Patents by Inventor Anil Mahadeo Rane

Anil Mahadeo Rane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11926642
    Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: March 12, 2024
    Assignee: Pfizer inc.
    Inventors: Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
  • Patent number: 11891373
    Abstract: This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
    Type: Grant
    Filed: October 6, 2021
    Date of Patent: February 6, 2024
    Assignee: Pfizer Inc.
    Inventors: Eric Christian Hansen, Christopher Scott Seadeek, Anil Mahadeo Rane
  • Publication number: 20220127274
    Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.
    Type: Application
    Filed: January 10, 2022
    Publication date: April 28, 2022
    Applicant: Pfizer Inc.
    Inventors: Kapildev Kashmirilal Arora, Jacob Cole DeForest, Andrew Kevern Hills, Brian Patrick Jones, Kris Nicole Jones, Chad Arthur Lewis, Anil Mahadeo Rane
  • Patent number: 11254684
    Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: February 22, 2022
    Assignee: Pfizer Inc.
    Inventors: Kapildev Kashmirilal Arora, Jacob Cole DeForest, Andrew Kevern Hills, Brian Patrick Jones, Kris Nicole Jones, Chad Arthur Lewis, Anil Mahadeo Rane
  • Publication number: 20220024894
    Abstract: This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
    Type: Application
    Filed: October 6, 2021
    Publication date: January 27, 2022
    Applicant: PFIZER INC.
    Inventors: Eric Christian Hansen, Christopher Scott Seadeek, Anil Mahadeo Rane
  • Publication number: 20220017548
    Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.
    Type: Application
    Filed: July 1, 2021
    Publication date: January 20, 2022
    Applicant: Pfizer Inc.
    Inventors: Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Martin Youngjin Pettersson, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
  • Publication number: 20210009601
    Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.
    Type: Application
    Filed: September 29, 2020
    Publication date: January 14, 2021
    Applicant: Pfizer Inc.
    Inventors: Kapildev Kashmirilal Arora, Jacob Cole DeForest, Andrew Kevern Hills, Brian Patrick Jones, Kris Nicole Jones, Chad Arthur Lewis, Anil Mahadeo Rane
  • Patent number: 10815240
    Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: October 27, 2020
    Assignee: Pfizer Inc.
    Inventors: Kapildev Kashmirilal Arora, Jacob Cole DeForest, Andrew Kevern Hills, Brian Patrick Jones, Kris Nicole Jones, Chad Arthur Lewis, Anil Mahadeo Rane
  • Publication number: 20200123159
    Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.
    Type: Application
    Filed: July 3, 2019
    Publication date: April 23, 2020
    Applicant: Pfizer Inc.
    Inventors: Kapildev Kashmirilal Arora, Jacob Cole DeForest, Andrew Kevern Hills, Brian Patrick Jones, Kris Nicole Jones, Chad Arthur Lewis, Anil Mahadeo Rane